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 Summary
 Background: Autoimmune hypophysitis (AH) is a rare inflammatory condition of the pituitary gland and 
usually affects women of childbearing age. It commonly leads to pituitary dysfunction. Moreover, 
pituitary enlargement may lead to compressive symptoms, which necessitates urgent surgical 
decompression. Resection of the pituitary gland causes iatrogenic hypopituitarism which requires 
lifelong hormonal supplementation. With an increasing number of suspected cases of pituitary 
diseases, there has been a paradigm shift in the management by conservative measures, especially, 
when surgery is not urgently needed.
 Case Report: We report a case of AH in a premenopausal woman presenting with headache. MRI revealed a 
solid-cystic mass involving the anterior lobe of the pituitary gland. The infundibulum was also 
thickened and enhancing; however, it was still in the midline. Ancillary MRI findings and hormonal 
profile were favouring the diagnosis of AH over pituitary neoplasm. The patient was managed 
conservatively with high doses of glucocorticoids, which resulted in prompt resolution of the 
lesion. During subsequent follow-up over 6 years, there was no recurrence and partial restoration 
of the pituitary function was seen. This case is interesting due to an unusual MRI appearance of 
AH, presenting as a solid-cystic mass. Moreover, disease resolution with conservative treatment 
strengthens the approach to limit surgery to those patients with compressive symptoms or 
uncertain diagnosis.
 Conclusions: AH should be included in the differential diagnosis of solid-cystic pituitary masses along with 
clinical correlation, which includes early involvement of ACTH and TSH and a relatively rapid 
development of hypopituitarism. In uncertain cases or with lack of compressive symptoms, a trial 
of steroids is worthwhile.
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Background
AH is a rare inflammatory condition of the pituitary gland 
which usually presents with compressive symptoms or hor-
monal dysfunction secondary to hypopituitarism. Although 
any sellar mass may lead to pituitary dysfunction, the pat-
tern of hormonal involvement may herald a suspicion of 
AH on clinical grounds. The usual MRI appearance of AH 
involves pituitary enlargement with solid homogeneous 
enhancement. Rarely, there may be cystic degeneration, 
hence, making AH indistinguishable from neoplasms. Despite 
being a non-neoplastic condition, surgical management is 
essential to relieve compressive symptoms. Furthermore, 
confirmatory diagnosis is established by histopathology of 
the resected specimen. However, a major disadvantage of 
surgery is the subsequent development of iatrogenic hypopi-
tuitarism which necessitates lifelong hormonal supplementa-
tion. Because of that, physicians currently prefer an initial 
trial of conservative management in cases provisionally diag-
nosed as AH on the basis of characteristic clinical and radi-
ological findings. This approach is particularly indicated in 
individuals with non-emergency clinical manifestations. [1,2].
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C A S E  R E P O R T
Case Report
A 50-year-old premenopausal, multiparous woman with 
pre-existing diabetes mellitus presented with insidiously 
progressing, persistent headache for 2 months. She also 
complained of fatigue, cold intolerance, facial puffiness, 
galactorrhoea and oligomenorrhoea. No significant past 
history of infection, systemic illness or any visual abnor-
mality was present. Chest X-ray, abdominal ultrasound and 
digital perimetry were normal.
CECT of the head performed as part of a routine evaluation 
for headache, revealed an incidental sellar mass. For fur-
ther evaluation and delineation of its extent, MRI was per-
formed (Figure 1A–1D). It showed circumscribed enlarge-
ment of the anterior lobe of the pituitary gland, especial-
ly involving its right lateral lobe. It was predominantly 
hypointense on T1WI and of heterogeneous signal intensity 
on T2WI. On postcontrast scans, there was intense periph-
eral enhancement. However, lack of central enhancement 
led to a mixed solid-cystic appearance. Pituitary stalk was 
also thickened and intensely enhancing. It was compress-
ing the chiasma, but there was no stalk deviation. Posterior 
pituitary bright spot was absent. There was no cavern-
ous sinus invasion, encasement of the internal carotid or 
extracranial  extension (Figure 2A, 2B). The floor of the 
sella turcica was intact, as evidenced on CT.
Endocrinal evaluation revealed marginal hyperprolactine-
mia and panhypopituitarism with reduction in FT4, gon-
adotropin and cortisol production. Serum TSH was within 
the lowest quartile of normal limits. Serum LH was unde-
tectable which was abnormal in a postmenopausal women 
(Table 1). No clinical or biochemical evidence of diabetes 
insipidus was present. These findings were suggestive of 
exclusive involvement of the anterior lobe of the pituitary 
gland.
In summary, the clinicoradiological findings included:
i)  Characteristic pattern of pituitary dysfunction with 
early loss of adrenocorticotrophic hormone and thyroid-
stimulating hormone;
ii)  Relatively rapid development of hypopituitarism;
iii)  Characteristic MRI features such as near-symmetric 
enlargement of the pituitary gland, thickened but non-
displaced stalk with strong contrast enhancement.
Considering the subacute presentation, pattern of endo-
crine involvement and radiological features, a diagnosis of 
autoimmune hypophysitis was most probable. A pituitary 
Figure 1.  (A, B) T2W sagittal and coronal images (A, B) showed a well-defined, heterogeneously hypointense enlargement (7.8×7.9 mm) of 
the anterior pituitary lobe (arrow). (C, D) Postcontrast coronal and sagittal images (C, D) showing intense, peripheral enhancement of 
the pituitary gland; however, the centre of the lesion was non-enhancing resulting in solid-cystic appearance. The pituitary stalk was 
also thickened and intensely enhancing (arrow in D); nonetheless, it was maintained in the midline. There was indentation on the optic 
chiasma (curved arrow in C); although there were no visual complaints.
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macroadenoma was the next differential consideration due 
to certain atypical MRI findings such as cystic degenera-
tion. However, pituitary macroadenomas (benign or malig-
nant) usually cause deviation of the pituitary stalk and 
bone destruction, which was not present in this case. As 
the patient was stable without any manifestations requir-
ing urgent neurosurgical intervention, a decision on ini-
tial conservative management was made on the basis of 
the presumptive diagnosis of AH. Immunosuppressive 
doses of oral glucocorticoids were given initially for 10 
weeks. Furthermore, initiation and up-titration of thyroxin 
replacement was done.
After 4 weeks, there was a remarkable clinical improve-
ment and significant reduction in the overall size of the 
mass on MRI (Figure 2C, 2D). The cystic component had 
also significantly regressed. After 10 weeks, follow-up 
MRI (Figure 2E, 2F) revealed near-complete resolution of 
the lesion with persistence of only a small cystic remnant. 
In the following months, thyroxin and glucocorticoid sup-
plementations were continued (Table 2). After 11 months, 
glucocorticoid supplementation was withdrawn. During 
the subsequent follow-up over 6 years, thyroxin supple-
mentation was continued. There were no new complaints. 
Serum cortisol levels remained within the normal range. 
However, serum gonadotropin levels had been persistent-
ly low since the onset, signifying lack of recovery of gon-
adotropin secretion. A recent MRI scan, performed after 6 
years, revealed a partially empty sella with complete disap-
pearance of the pituitary lesion (Figure 2G, 2H).
Discussion
Inflammatory lesions of the pituitary gland, also referred 
to as hypophysitis, are broadly categorized aetio-
logically into 4 subtypes – purulent, granulomatous, 
Hormonal level Value Reference range
a) Prolactin 55.64 ng/mL 2.74–19.64 ng/mL
b) FT4 0.63 ng/dL 0.7–1.8 ng/dL
c) S.TSH 1.19 µIU/mL 0.3–5.5 µIU/ml 
d) Serum cortisol 1.58 µg/dL 5–25 µg/dL 
e) Serum LH Undetectable 11.3–39.8 IU/L
Table 1. Endocrinal profile at presentation.
FT4 – free thyroxine; S.TSH – serum Thyroid-Stimulating Hormone.
Figure 2.  Serial MRI scans of the sella over 6 years, postcontrast (except G and H) coronal (top row) and sagittal images (bottom row) for 
comparative analysis. At initial presentation (A, B), the anterior lobe of the pituitary gland was enlarged with a solid-cystic appearance 
(arrow in A). Pituitary stalk was also thickened (arrow in B). At 4 weeks (C, D), a significant reduction in the size of the lesion (arrow in C) 
and thickness of the pituitary stalk are seen (arrow in D). (E, F) At 10 weeks, a near-complete disappearance of the mass with persistence 
of a tiny cystic remnant is seen (arrow in E). The height of the pituitary gland was also decreased with a flattened upper margin (arrow 
in F), unusual for a multipara. (G, H) At 6 years, a partial empty sella, thinned pituitary stalk (arrow in G, H) and absence of lesion were 
noted.
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Serum LH ≤0.001 IU/L(expected >20 IU/L)
Serum FT4=2.29 (0.8–1.9) ng/dL
Serum Cortisol=ND
Serum GH=ND
Serum prolactin=47.3(2.5–17) ng/mL
Tests for DI negative
Table 2. Endocrine tests at 10 weeks follow up.
LH – luteinizing hormone; FT4 – free thyroxine; GH – growth 
hormone; DI – diabetes insipidus; ND – not detectable.
Feature Autoimmune hypophysitis Pituitary macroadenoma 
MRI findings
a) Asymmetric mass Rare +
a) Pre contrast homogeneous signal + (Uncommonly heterogeneous if 
cystic degeneration)
–
c) Intact sellar floor (accurately assessed on CT) + –
d) Suprasellar extension + +
e) Stalk thickening + -
f) Stalk displacement - +
g) Homogeneous enhancement + _
h) Loss of hyperintensity of posterior pituitary bright spot +/– –
i) Endocrinal dysfunction Relatively rapid development of 
hypopituitarism
Early involvement of ACTH and TSH
Early involvement of growth hormone 
followed by gonadotrophins
Table 3. Comparative analysis of MRI findings and pattern of pituitary hormone in autoimmune hypophysitis and pituitary macroadenoma [6–8].
lymphocytic or secondary to an associated pathological 
process. Autoimmune hypophysitis (AH) or lymphocytic 
hypophysitis is an extremely rare entity. It usually affects 
women of childbearing age, during pregnancy or in the 
immediate post-partum period, which strongly suggests 
an autoimmune basis. Uncommonly, it may occur in post-
menopausal women and in men. Anatomically, based on 
pituitary lobe involvement, it may be further classified 
into: adenohypophysitis, infundibulo-neurohypophysitis or 
panhypophysitis; the former being the most common [1–5].
Clinically, AH is usually subacute in onset and manifests 
with a relatively rapidly developing panhypopituitarism 
with an early involvement of ACTH and TSH secretion. 
Confirmatory diagnosis of AH is essentially established on 
histopathology of the resected specimen, in which lym-
phocyte and plasma cell infiltration is seen. Organ-specific 
antibodies may be present in some cases [1,4]. With an ever 
increasing role of MRI in the evaluation of sellar/supra-
sellar lesions, AH may be suspected non-invasively by the 
presence of certain features in a pituitary lesion. It charac-
teristically causes symmetric enlargement of the anterior 
lobe of the pituitary gland, which usually shows intense 
homogeneous enhancement, comparable to the cavern-
ous sinus. The infundibulum may be thickened; however, 
due to the symmetric enlargement of pituitary gland, there 
is no stalk deviation. Uncommonly, there may be central 
necrosis, which appears cystic due to lack of enhance-
ment. Differential considerations of AH include pituitary 
macroadenoma from which it can be distinguished by con-
sidering collective clinico-radiological findings (Table 3). 
Hormonal profile and especially the pattern of involvement 
of pituitary hormones may help arrive at the diagnosis in 
certain cases. Solid-cystic sellar masses on imaging, as in 
our case, may resemble pituitary macroadenomas in which 
cystic degeneration is fairly common. However, deviation 
of the pituitary stalk is usually present in macroadenomas 
due to asymmetrical involvement. Furthermore, there is no 
thickening of the stalk, in contrast to our case [5–8].
Due to the pituitary enlargement and its consequent mass 
effect, AH requires urgent neurosurgical intervention. 
Surgery is also indicated in certain indeterminate cases 
which are indistinguishable from pituitary neoplasms 
(commonly macroadenoma). Following surgery, compres-
sive symptoms are relieved; however, endocrinological 
dysfunction persists, resulting in iatrogenic hypopituita-
rism requiring lifelong hormonal supplementation. Hence, 
nowadays a trial of conservative management with ster-
oids is worthwhile, especially. in the absence of compres-
sive symptoms [1,2].
In our case, a significant reduction in the size of the mass 
within 4 weeks of glucocorticoid treatment initiation might 
have resulted from suppression of inflammatory activity. 
This case also highlights the possibility of recovery of hor-
mone production after complete insufficiency during the 
active inflammatory phase. Long-term studies have docu-
mented that while 73% of patients required replacement of 
Case Report © Pol J Radiol, 2017; 82: 473-477
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at least one hormone. However, in approximately 16% of 
cases no hormonal supplementation was required [9–11].
No long-term data on the benefits of surgical treatment 
over medical management are available. Moreover, only 
short-term follow-up of surgical cases is available in the 
literature; however, it suggests recovery in the major-
ity of cases. Nonetheless, few reports suggest recurrence 
with iatrogenic hypopituitarism in a significant proportion 
of cases, in in particular ,diabetes mellitus. For the rea-
sons mentioned above, most authors prefer a conservative 
approach whenever feasible. Nonetheless, the precondition 
for conservative management is a non-invasive diagnosis 
of AH, which requires clinicians to be acquainted with its 
clinical and imaging features. [9,10]
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Conclusions
AH is rare but increasingly recognized. It should be con-
sidered in the differential diagnosis of any non-secreting 
pituitary mass, especially in women. In the absence of 
surgical emergency (for e.g. impending vision loss), medi-
cal management, medical management, i.e. monitoring the 
patient’s endocrine status combined with sequential MRI 
imaging, is preferable. However, this approach precludes 
a definitive pathologic diagnosis. If symptoms persist or 
worsen, or if the patient does not tolerate high doses of glu-
cocorticoids, transsphenoidal surgery should be performed.
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